A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants

Signal Transduct Target Ther. 2022 Jan 25;7(1):23. doi: 10.1038/s41392-022-00879-2.

Xiaomin Duan^#^{1

2}, Rui Shi^#¹, Pulan Liu^#³, Qingrui Huang¹, Fengze Wang^{1

2}, Xinyu Chen^{1

2}, Hui Feng⁴, Weijin Huang⁵, Junyu Xiao⁶, Jinghua Yan^{7

8}

¹ CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
² University of Chinese Academy of Sciences, Beijing, 100049, China.
³ State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Beijing Advanced Innovation Center for Genomics, Peking University, Beijing, 100871, China.
⁴ Shanghai Junshi Biosciences Co. Ltd, Shanghai, 200126, China.
⁵ Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China. [email protected].
⁶ State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Beijing Advanced Innovation Center for Genomics, Peking University, Beijing, 100871, China. [email protected].
⁷ CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China. [email protected].
⁸ University of Chinese Academy of Sciences, Beijing, 100049, China. [email protected].

^# Contributed equally.

No abstract available

Publication types